NPC
SRPT icon

National Planning Corporation’s Sarepta Therapeutics SRPT Stock Holding History

National Planning Corporation’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,023
Closed -$228K – 537
2017
Q3 		$228K Sell
5,023
-800
-14% -$32K 0.02% 593
2017
Q2 		$203K Sell
5,823
-2,850
-33% -$92.8K 0.02% 681
2017
Q1 		$250K Sell
8,673
-5,600
-39% -$173K 0.02% 565
2016
Q4 		$413K Sell
14,273
-1,500
-10% -$60.2K 0.03% 417
2016
Q3 		$613K Sell
15,773
-280
-2% -$8.46K 0.05% 321
2016
Q2 		$410K Buy
16,053
+2,375
+17% +$44K 0.03% 420
2016
Q1 		$242K Buy
13,678
+275
+2% +$4.8K 0.02% 529
2015
Q4 		$164K Buy
13,403
+3,130
+30% +$101K 0.01% 659
2015
Q3 		$258K Buy
10,273
+3,000
+41% +$102K 0.02% 496
2015
Q2 		$244K Buy
+7,273
New +$149K 0.02% 522
2015
Q1 		– Sell
-7,623
Closed -$114K – 1864
2014
Q4 		$114K Buy
+7,623
New +$129K 0.01% 870

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

National Planning Corporation's SRPT Position: Q4 2017 in Review

National Planning Corporation sold out of Sarepta Therapeutics (SRPT) in Q4 2017, closing a stake of 5,023 shares — an estimated $228K sold.

National Planning Corporation first reported a position in SRPT in Q4 2014 and held it in 11 quarters. The position peaked at $613K in Q3 2016. 254 funds tracked by Wall St. Rank hold SRPT as of Q4 2017.

  • National Planning Corporation reported no remaining Sarepta Therapeutics position as of Q4 2017 after selling out during the quarter.
  • National Planning Corporation sold 5,023 Sarepta Therapeutics shares in Q4 2017, an estimated $228K.
  • National Planning Corporation first reported a position in Sarepta Therapeutics in Q4 2014 and held it in 11 quarters.
  • National Planning Corporation's Sarepta Therapeutics position peaked at $613K in Q3 2016.
  • 254 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2017.

Based on National Planning Corporation's 13F filing for Q4 2017, filed 14 Feb 2018.